Q&A: Drug and Medical Device Litigation
Product Liability – Life Sciences Team Leader Eric Alexander was quoted in a Financier Worldwide Q&A on emerging product liability trends in the drug and medical device sector. Mr. Alexander spotlighted the key regulatory updates from the U.S. Food and Drug Administration (FDA) as well as legislative changes that may lead to increased litigation on vaccines and other medical products and technology, including artificial intelligence (AI). He also noted that policies for the use of AI in drug development will change as technology continues to evolve, advising companies to adopt early, coordinated plans across corporate, regulatory and government relations initiatives.
"The full impact of changes to FDA policies related to the current secretary of health and human services remains to be seen, but some recent cases have echoed these changes. Courts seem to be expanding traditional tort theories to accommodate liability for social media platforms, self-driving cars and other tech-driven 'products,'" Mr. Alexander said.
Life sciences regulatory attorney Sara Klock also contributed to this article.